The Management of Hypertension With Angiotensin Receptor Blockers in Special Populations

Rosamond, 2008, Heart disease and stroke statistics—2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, 117, e25, 10.1161/CIRCULATIONAHA.107.187998 Chobanian, 2003, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report [published correction appears in JAMA. 2003;290:197], JAMA, 289, 2560, 10.1001/jama.289.19.2560 Mancia, 2007, 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), J Hypertens, 25, 1105, 10.1097/HJH.0b013e3281fc975a Williams, 2004, British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): Summary [published correction appears in BMJ. 2004;328:926], BMJ, 328, 634, 10.1136/bmj.328.7440.634 2009 Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161 Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303 Parving, 2001, The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, N Engl J Med, 345, 870, 10.1056/NEJMoa011489 Mann, 2008, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial, Lancet, 372, 547, 10.1016/S0140-6736(08)61236-2 Mogensen, 2000, Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan and Lisinopril Microalbuminuria (CALM) study, BMJ, 321, 1440, 10.1136/bmj.321.7274.1440 Viberti, 2002, Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect, Circulation, 106, 672, 10.1161/01.CIR.0000024416.33113.0A Barnett, 2004, Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy [published correction appears in N Engl J Med. 2005;352:1731], N Engl J Med, 351, 1952, 10.1056/NEJMoa042274 Pitt, 2000, Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial—the Losartan Heart Failure Survival Study ELITE II, Lancet, 355, 1582, 10.1016/S0140-6736(00)02213-3 Cohn, 2001, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N Engl J Med, 345, 1667, 10.1056/NEJMoa010713 Pfeffer, 2003, Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme, Lancet, 362, 759, 10.1016/S0140-6736(03)14282-1 Yusuf, 2000, N Engl J Med, 342, 145, 10.1056/NEJM200001203420301 Pfeffer, 2003, Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [published correction appears in N Engl J Med. 2004;350:203], N Engl J Med, 349, 1893, 10.1056/NEJMoa032292 ONTARGET Investigators, 2008, Telmisartan, ramipril, or both in patients at high risk for vascular events, N Engl J Med, 358, 1547, 10.1056/NEJMoa0801317 Dahlöf, 2002, Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol, Lancet, 359, 995, 10.1016/S0140-6736(02)08089-3 Schrader, 2005, Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: Principal results of a prospective randomized controlled study (MOSES), Stroke, 36, 1218, 10.1161/01.STR.0000166048.35740.a9 Yusuf, 2008, Telmisartan to prevent recurrent stroke and cardiovascular events, N Engl J Med, 359, 1225, 10.1056/NEJMoa0804593 Reboldi, 2008, Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: A meta-analysis, J Hypertens, 26, 1282, 10.1097/HJH.0b013e328306ebe2 Krumholz, 2006, J Am Coll Cardiol, 47, 236, 10.1016/j.jacc.2005.10.020 Yusuf, 2008, Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial [published correction appears in Lancet. 2008;372:1384], Lancet, 372, 1174, 10.1016/S0140-6736(08)61242-8 Ferdinand, 2003, Recommendations for the management of special populations: Racial and ethnic populations, Am J Hypertens, 16, 50S, 10.1016/j.amjhyper.2003.07.007 Chan, 2004, Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study, Diabetes Care, 27, 874, 10.2337/diacare.27.4.874 2002, JAMA, 288, 2981, 10.1001/jama.288.23.2981 Julius, 2004, Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The LIFE study, J Am Coll Cardiol, 43, 1047, 10.1016/j.jacc.2003.11.029 Weir, 2001, Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: Relation to salt intake, Am J Hypertens, 14, 665, 10.1016/S0895-7061(01)01296-1 Weir, 2005, A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives, Hypertension, 46, 508, 10.1161/01.HYP.0000180457.82483.6b Law, 2003, Lowering blood pressure to prevent myocardial infarction and stroke: A new preventive strategy, Health Technol Assess, 7, 1, 10.3310/hta7310 Conlin, 2001, Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes, Clin Ther, 23, 1999, 10.1016/S0149-2918(01)80152-1 Julius, 2006, Feasibility of treating prehypertension with an angiotensin-receptor blocker, N Engl J Med, 354, 1685, 10.1056/NEJMoa060838 Lindholm, 2003, Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study), J Hypertens, 21, 1563, 10.1097/00004872-200308000-00022 DREAM Trial Investigators, 2006, Effect of ramipril on the incidence of diabetes, N Engl J Med, 355, 1551, 10.1056/NEJMoa065061